Lexaria Bioscience (LEXX) Current Assets (2011 - 2026)

Lexaria Bioscience has disclosed Current Assets across 16 years of filings, most recently posting $5.8 million for Q1 2026.

• Current Assets for Q1 2026 came in at $5.8 million, down 25.3% year-over-year; the trailing twelve-month figure through Feb 2026 was $5.8 million (down 25.3% YoY), and the FY2025 annual result was $3.5 million, down 56.09% from the prior year.
• Current Assets came in at $5.8 million for Q1 2026 at Lexaria Bioscience, up from $5.4 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $10.6 million in Q1 2022 to a low of $2.2 million in Q3 2023.
• The 5-year median for Current Assets is $5.8 million (2026), against an average of $6.1 million.
• Across the five-year window, Current Assets slumped 69.17% in 2023 and soared 267.14% in 2024, its largest moves.
• Lexaria Bioscience's Current Assets stood at $5.4 million in 2022, then tumbled by 49.74% to $2.7 million in 2023, then soared by 227.65% to $8.8 million in 2024, then tumbled by 39.23% to $5.4 million in 2025, then grew by 7.59% to $5.8 million in 2026.
• The last three Current Assets figures came in at $5.8 million (Q1 2026), $5.4 million (Q4 2025), and $3.5 million (Q3 2025), per Business Quant data.